Navigation Links
Combating cancer's double whammy
Date:11/11/2010

It can be fatal if the clot breaks away and lodges in the lung (pulmonary embolism). The aim of this analysis of primary care data is to establish a clearer picture of the increased risk of venous thromboembolism in different cancers, and to help create bespoke guidelines for doctors in how to prevent the condition arising after a cancer diagnosis.

The three year study is being carried out in the University's Division of Epidemiology and Public Health. Researchers believe that some 3,000 deaths a year in cancer patients from VTE could potentially be prevented using cheap and safe preventative treatments known as thromboprophylaxis when targeted at the most appropriate times; the most widely used are warfarin and heparin.

The researchers will use three UK health databases to analyse information from 100,000 cancer patients between 2001 and 2009 and compare these cases with a random sample of 500,000 people without cancer. All the data collected from the General Practice Research Database, the Hospital Episode Statistics database and Cancer Registries, will be anonymous.

Lead researcher and epidemiologist, Dr Matthew Grainge, said: "We know that cancer can trigger clotting in the venous system and cancer treatments like surgery and chemotherapy can increase this risk further. This detailed analysis will show us more precisely when people with cancer are at greatest risk of venous thromboembolism compared with the general population within periods defined by cancer treatment, time since diagnosis and hospitalisation. We will also be comparing occurrence and risks in over 20 different types of cancer."

Clinical Associate Professor in the Department of Community Health Sciences, Joe West, said: "At the moment there is little clear guidance for clinicians on preventative treatment for this dangerous condition which is more prevalent among cancer patients. Epidemiological studies like this are vital in the fight to cut the numb
'/>"/>

Contact: Emma Rayner
emma.rayner@nottingham.ac.uk
44-115-951-5793
University of Nottingham
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Holistic Management and Allan Savory Win the 2010 Buckminster Fuller Award for Turning Deserts into Thriving Grasslands and Combating Climate Change.
2. Texas Center for Cancer Nanomedicine targets 2 tough cancers
3. New Drug Shows Promise Against Certain Lung Cancers
4. Tumor suppressor acts as oncogene in some cancers, say Mayo Clinic researchers
5. Surprise finding: Pancreatic cancers progress to lethal stage slowly
6. Healthy Living Can Prevent Nearly 25% of Colorectal Cancers
7. New Finding Suggests Safe Surgical Margins When Removing Breast Cancers
8. Duke vaccine extends survival for patients with deadly brain cancers
9. New device for identifying aggressive breast cancers
10. A revolutionary new way of reversing certain cancers
11. Radiation exposure poses similar risk of first and second cancers in atomic bomb survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... fruitful, lead in ongoing investigation into salmonella outbreak , , ... U.S. government investigation into salmonella-tainted tomatoes has not yet ... said Monday they are now focusing their trace-back efforts ... , "The cluster is linked to the same ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received tentative approval from the U.S. Food ... Application (ANDA) for Irbesartan and,Hydrochlorothiazide Tablets, 150 mg/12.5 ... Hydrochlorothiazide Tablets, indicated for the treatment,of hypertension, are ...
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... of agents that inhibit the growth of estrogen-dependent breast ... of the Endocrine Society, has opened an avenue of ... , "This cell-based study is exciting because it suggests ... that remain dependent on estrogen for growth but are ...
... could be the next generation of treatments, researchers say ... identified a new group of compounds that might one ... to fight estrogen-fueled breast cancer. , "This is a ... Dr. Len Lichtenfeld, deputy chief medical officer of the ...
... June 16 The National Center for Healthcare,Leadership ... Gabow, MD, chief,executive officer of Denver Health, as ... for her significant and lasting contributions,to healthcare. Under ... healthcare system that achieves organizational,excellence while treating at-risk ...
Cached Medicine News:Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 2Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 3Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs ... facility in Albany, NY for ... The company meets and/or exceeds the FDA standards for ... 21 CFR Part 211. The 10,000 ... highest levels of quality assurance and quality control. The ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Anlit Advanced Nutrition Supplements , an ... for children, will present new and innovative products at ... 2012 in Geneva, Switzerland. Anlit will showcase new ... at Stand 3500. The company will present, among others, ...
... 2012  Luminex Corporation (NASDAQ: LMNX ) today announced ...  Financial and operating highlights include the following: , ... increase over the first quarter of 2011 , First ... over the first quarter of 2011 , First quarter ...
Cached Medicine Technology:Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012 2Luminex Corporation Reports First Quarter 2012 Results 2Luminex Corporation Reports First Quarter 2012 Results 3Luminex Corporation Reports First Quarter 2012 Results 4Luminex Corporation Reports First Quarter 2012 Results 5Luminex Corporation Reports First Quarter 2012 Results 6Luminex Corporation Reports First Quarter 2012 Results 7Luminex Corporation Reports First Quarter 2012 Results 8
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-Diluent CD is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1800....
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
Medicine Products: